The α3β4 nicotinic acetylcholine receptor antagonist 18-Methoxycoronaridine decreases binge-like ethanol consumption in adult C57BL/6J mice

Carley N. Miller, Colton Ruggery, Helen Marie Kamens

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    Binge alcohol drinking is a health burden in the United States, which has an alarming economic impact. Unfortunately, medications available for alcohol abuse have low efficacy or adverse side effects, creating a need to evaluate novel therapies. Growing research suggests that 18-Methoxycoronaridine (18-MC), an α3β4 nicotinic acetylcholine receptor (nAChR) antagonist, may be effective at reducing ethanol consumption. However, its effects on binge-like ethanol consumption and other ethanol behaviors have not been examined. The present study examined the effect of α3β4 nAChRs antagonism on basal locomotor activity in male and female C57BL/6J mice. Next we tested the effect of 18-MC on binge-like ethanol consumption, ethanol-induced sedation, and ethanol metabolism. Finally, we tested the effect of α3β4 nAChRs on saccharin consumption to ensure effects were specific for ethanol. We observed that 18-MC decreased binge-like ethanol consumption without altering saccharin consumption, the sedative effects of ethanol, or ethanol metabolism. High doses of 18-MC caused locomotor sedation in C57BL/6J mice, but the effects were brief and likely did not contribute to differences in ethanol consumption. Our results support the involvement of the α3β4 nAChRs in binge-like ethanol intake, and further work should explore the use of 18-MC for treatment of alcohol use disorders.

    Original languageEnglish (US)
    Pages (from-to)1-6
    Number of pages6
    JournalAlcohol
    Volume79
    DOIs
    StatePublished - Sep 1 2019

    Fingerprint

    Nicotinic Receptors
    Cholinergic Antagonists
    Inbred C57BL Mouse
    Ethanol
    alcohol
    Saccharin
    Alcohols
    Metabolism
    18-methoxycoronaridine
    antagonism
    economic impact
    Binge Drinking
    medication
    abuse
    Locomotion
    Hypnotics and Sedatives
    Alcohol Drinking
    Alcoholism
    health
    Economics

    All Science Journal Classification (ASJC) codes

    • Health(social science)
    • Biochemistry
    • Toxicology
    • Neurology
    • Behavioral Neuroscience

    Cite this

    @article{4041e75ecefc445090c0c045dee94a10,
    title = "The α3β4 nicotinic acetylcholine receptor antagonist 18-Methoxycoronaridine decreases binge-like ethanol consumption in adult C57BL/6J mice",
    abstract = "Binge alcohol drinking is a health burden in the United States, which has an alarming economic impact. Unfortunately, medications available for alcohol abuse have low efficacy or adverse side effects, creating a need to evaluate novel therapies. Growing research suggests that 18-Methoxycoronaridine (18-MC), an α3β4 nicotinic acetylcholine receptor (nAChR) antagonist, may be effective at reducing ethanol consumption. However, its effects on binge-like ethanol consumption and other ethanol behaviors have not been examined. The present study examined the effect of α3β4 nAChRs antagonism on basal locomotor activity in male and female C57BL/6J mice. Next we tested the effect of 18-MC on binge-like ethanol consumption, ethanol-induced sedation, and ethanol metabolism. Finally, we tested the effect of α3β4 nAChRs on saccharin consumption to ensure effects were specific for ethanol. We observed that 18-MC decreased binge-like ethanol consumption without altering saccharin consumption, the sedative effects of ethanol, or ethanol metabolism. High doses of 18-MC caused locomotor sedation in C57BL/6J mice, but the effects were brief and likely did not contribute to differences in ethanol consumption. Our results support the involvement of the α3β4 nAChRs in binge-like ethanol intake, and further work should explore the use of 18-MC for treatment of alcohol use disorders.",
    author = "Miller, {Carley N.} and Colton Ruggery and Kamens, {Helen Marie}",
    year = "2019",
    month = "9",
    day = "1",
    doi = "10.1016/j.alcohol.2018.11.006",
    language = "English (US)",
    volume = "79",
    pages = "1--6",
    journal = "Alcohol",
    issn = "0741-8329",
    publisher = "Elsevier Inc.",

    }

    The α3β4 nicotinic acetylcholine receptor antagonist 18-Methoxycoronaridine decreases binge-like ethanol consumption in adult C57BL/6J mice. / Miller, Carley N.; Ruggery, Colton; Kamens, Helen Marie.

    In: Alcohol, Vol. 79, 01.09.2019, p. 1-6.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - The α3β4 nicotinic acetylcholine receptor antagonist 18-Methoxycoronaridine decreases binge-like ethanol consumption in adult C57BL/6J mice

    AU - Miller, Carley N.

    AU - Ruggery, Colton

    AU - Kamens, Helen Marie

    PY - 2019/9/1

    Y1 - 2019/9/1

    N2 - Binge alcohol drinking is a health burden in the United States, which has an alarming economic impact. Unfortunately, medications available for alcohol abuse have low efficacy or adverse side effects, creating a need to evaluate novel therapies. Growing research suggests that 18-Methoxycoronaridine (18-MC), an α3β4 nicotinic acetylcholine receptor (nAChR) antagonist, may be effective at reducing ethanol consumption. However, its effects on binge-like ethanol consumption and other ethanol behaviors have not been examined. The present study examined the effect of α3β4 nAChRs antagonism on basal locomotor activity in male and female C57BL/6J mice. Next we tested the effect of 18-MC on binge-like ethanol consumption, ethanol-induced sedation, and ethanol metabolism. Finally, we tested the effect of α3β4 nAChRs on saccharin consumption to ensure effects were specific for ethanol. We observed that 18-MC decreased binge-like ethanol consumption without altering saccharin consumption, the sedative effects of ethanol, or ethanol metabolism. High doses of 18-MC caused locomotor sedation in C57BL/6J mice, but the effects were brief and likely did not contribute to differences in ethanol consumption. Our results support the involvement of the α3β4 nAChRs in binge-like ethanol intake, and further work should explore the use of 18-MC for treatment of alcohol use disorders.

    AB - Binge alcohol drinking is a health burden in the United States, which has an alarming economic impact. Unfortunately, medications available for alcohol abuse have low efficacy or adverse side effects, creating a need to evaluate novel therapies. Growing research suggests that 18-Methoxycoronaridine (18-MC), an α3β4 nicotinic acetylcholine receptor (nAChR) antagonist, may be effective at reducing ethanol consumption. However, its effects on binge-like ethanol consumption and other ethanol behaviors have not been examined. The present study examined the effect of α3β4 nAChRs antagonism on basal locomotor activity in male and female C57BL/6J mice. Next we tested the effect of 18-MC on binge-like ethanol consumption, ethanol-induced sedation, and ethanol metabolism. Finally, we tested the effect of α3β4 nAChRs on saccharin consumption to ensure effects were specific for ethanol. We observed that 18-MC decreased binge-like ethanol consumption without altering saccharin consumption, the sedative effects of ethanol, or ethanol metabolism. High doses of 18-MC caused locomotor sedation in C57BL/6J mice, but the effects were brief and likely did not contribute to differences in ethanol consumption. Our results support the involvement of the α3β4 nAChRs in binge-like ethanol intake, and further work should explore the use of 18-MC for treatment of alcohol use disorders.

    UR - http://www.scopus.com/inward/record.url?scp=85063456838&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85063456838&partnerID=8YFLogxK

    U2 - 10.1016/j.alcohol.2018.11.006

    DO - 10.1016/j.alcohol.2018.11.006

    M3 - Article

    C2 - 30496781

    AN - SCOPUS:85063456838

    VL - 79

    SP - 1

    EP - 6

    JO - Alcohol

    JF - Alcohol

    SN - 0741-8329

    ER -